SEC Form 4 · accession 0000899243-18-022840
Global Blood Therapeutics, Inc. · GBT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Lesley Ann Calhoun
Officer — See Remarks
Period of report
Aug 16, 2018
Accepted (ET)
Aug 20, 2018 · 8:25 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001629137
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jul 31, 2018 | A | 204 | $35.53 | A | 1,342 | D | |
| Common Stock | Aug 16, 2018 | S | 204 | $49.969 | D | 1,138 | D | |
| Common Stock | Aug 16, 2018 | M | 500 | $22.00 | A | 1,638 | D | |
| Common Stock | Aug 16, 2018 | M | 1,000 | $22.00 | A | 2,638 | D | |
| Common StockF2 | Aug 16, 2018 | S | 1,500 | $50.0135 | D | 1,138 | D | |
| Common Stock | Aug 17, 2018 | S | 300 | $49.188 | D | 838 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $22.00 | Aug 16, 2018 | M | 500 | D | — | — | Common Stock | 500 | 26,205 | D |
| Stock Option (Right to Buy)F3 | $22.00 | Aug 16, 2018 | M | 1,000 | D | — | — | Common Stock | 1,000 | 25,205 | D |
Explanation of responses
- F1Shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan.
- F2Represents the weighted average sale price of the shares sold ranging from $50.0000 to $50.0304 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- F3The Stock Option becomes exercisable with respect to 1/4th of the underlying shares on August 15, 2017 and with respect to an additional 1/12th of the underlying shares each quarter thereafter until fully vested on August 15, 2020, subject to the Reporting Person's continuous service with the Issuer. The Stock Option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.
Remarks
Vice President, Finance and Principal Accounting Officer